Tetra Therapeutics
Manufacturing · Michigan, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2220 Wealthy St SE, Grand Rapids, Michig...Phone Number
(616) 224-0084Website
www.tetratherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Tetra Therapeutics
Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhibitors of phosphodiesterase 4 (PDE4), an enzyme family that plays key roles in memory formation, learning, neuroinflammation, and traumatic brain injury. Tetra Therapeutics is headquartered in Grand Rapids, Michigan.Explore more
Tetra Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tetra Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tetra Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Tetra Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Tetra Therapeutics recently announced quarterly report
Product Launch: Get notified when Tetra Therapeutics launches new products
Check out if Tetra Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Tetra Therapeutics
Click to see if Tetra Therapeutics had a recent Job posting/layoffs
Check if Tetra Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Tetra Therapeutics
Compare insights from companies similar to Tetra Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tetra Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tetra Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tetra Therapeutics.
Tetra Therapeutics financials insights
Gather financial insights about Tetra Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Other Financing Round
$1M
2016
Series A
$5M
2019
Angel/Seed
$1M
Tetra Therapeutics Tech Stack
A closer look at the technologies used by Tetra Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Move
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Tetra Therapeutics News & Media
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter "Tetra"), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism. FDA graTetra Therapeutics Initiates Phase 2b/3 Clinical Studies of Investigational Drug BPN14770 in Fragile X Syndrome
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Tetra Therapeutics, a Shionogi Group Company, focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, today announced the initiation of three Phase 2b/3 clinical studies of the investigational drug BPN14770 (zatolmilast) as a potential treatment for Fragile X Syndrome (FXS), the most common genetic form of autism. A selective small molecule inhibitor of phosphodiesterase‐4D (PDE4D), BPN1477Tetra Therapeutics names replacement for retired CEO
A local drug company has promoted its COO to CEO following the retirement of its top leader last month.Tetra Therapeutics Announces Retirement of Mark Gurney and Names Chad Coberly Chief Executive Officer in Planned Succession
GRAND RAPIDS, Mich.--(BUSINESS WIRE)--Tetra Therapeutics, a clinical stage biopharmaceutical company focused on the development of compounds for the treatment of brain disorders associated with cognitive and memory deficits, notably BPN14770, a selective inhibitor of phosphodiesterase‐4D (PDE4D), announced changes to its executive team as the company marks one year since the close of its merger with Shionogi & Co., Ltd.. Tetra Therapeutics currently operates as a wholly owned subsidiary of
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tetra Therapeutics
Sign Up For FreeTo access detailed company insights
Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. Tetra uses structure-guided drug design to discover mechanistically novel, allosteric inhi... Read More
